文献类型：期刊文献

英文题名：Transcatheter mitral valve replacement for degenerated mitral valve bioprostheses, failure of mitral valvuloplasty and native valve with severe mitral annulus calcification: a systematic review and meta-analysis

作者：You, Tao[1,2];Wang, Wei[2,3];Yi, Kang[1,2];Gao, Jie[2,3];Zhang, Xin[2,4];He, Shao-E.[2,5];Xu, Xiao-Min[2,3];Ma, Yu-Hu[2,3];Li, Xin-Yao[1,2,3]

第一作者：You, Tao

通信作者：You, T[1]

机构：[1]Gansu Prov Hosp, Dept Cardiovasc Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Int Sci & Technol Cooperat Base Diag & Trea, Lanzhou, Peoples R China;[3]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[4]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China

第一机构：Gansu Prov Hosp, Dept Cardiovasc Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Cardiovasc Surg, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2021

卷号：16

期号：1

外文期刊名：JOURNAL OF CARDIOTHORACIC SURGERY

收录：;Scopus(收录号：2-s2.0-85116847114);WOS:【SCI-EXPANDED(收录号:WOS:000705384700001)】；

基金：Natural Science Foundation of Gansu Province (21JR1RA027); Health industry scientific research project of Gansu Province (GSWSKY2016-04).

语种：英文

外文关键词：Mitral valve; TMVR; Valve-in-valve; Valve-in-ring; Valve-in-MAC; Systematic review; Meta-analysis

摘要：Background Although transcatheter technology has achieved some success in the field of mitral valves, the feasibility of applying it to patients with degenerated mitral valve bioprostheses (valve-in-valve, ViV), failure of mitral valvuloplasty (valve-in-ring, ViR) and serious mitral annulus calcification (vale-in-MAC, ViMAC) has not been effectively evaluated. Methods By searching published literature before December 5, 2020 in four databases, we found all the literature related to the evaluation of feasibility assessment of TMViV, TMViR and TMViMAC. Outcomes focused on all-cause mortality within 30 days, bleeding and LVOT obstruction. Results A total of six studies were included, and all of them were followed up for at least 30 days. After analysis of the ViV-ViR group, we obtained the following results: the all-cause mortality within 30 days of the ViV group was lower than that of the ViR group. Life-threatening or fatal bleeding was more likely to occur in the ViR group after surgery. At the same time, the ViR group was more prone to left ventricular outflow tract obstruction. However, in the ViMAC-ViR group, only the all-cause mortality within 30 days and stroke were statistically significant. In the indirect comparison, we found that TMViV had the best applicability, followed by TMViR. There were few TMViMAC available for analysis, and it requires further studies to improve the accuracy of the results. Conclusion TMViV and TMViR had good applicability and could benefit patients who underwent repeat valve surgery. The feasibility of TMViMAC needs to be further explored and improved.